UroAlert - GU Oncology Weekly

June 18, 2026

Videos

Peer-to-Peer Clinical Conversations

Computational AI for Predicting Grade Progression in Intermediate-Risk Bladder Cancer - Roger Li

Roger Li

Roger Li discusses an AI-based histomorphology predictor for intermediate-risk bladder cancer, built on the CHAI platform previously developed to predict BCG response.

SunRISe-1 Cohort 4 Analysis: One-Year Disease-Free Survival in BCG-Unresponsive Papillary Bladder Cancer - Siamak Daneshmand

Siamak Daneshmand

Siamak Daneshmand presents SunRISe-1 Cohort 4 one-year results for gemcitabine intravesical system (Gem-iDRS), INLEXZO™ (gemcitabine intravesical system; formerly TAR-200) in BCG-unresponsive papillary NMIBC.

Beyond the Abstracts

Immunotherapy Combinations in Favourable Risk Score Metastatic Renal Cell Carcinoma, an Individual Patients Data Metanalysis - Beyond the Abstract

Gender-Based Differences in Psychosocial Well-being Among Bladder Cancer Survivors - Beyond the Abstract

Conference Coverage

ASCO 2026: Bulumtatug Fuvedotin + Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Follow-up Results from a Phase 1b/2 Study

ASCO 2026: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After First Line Platinum Based Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (Alliance A032001)

ASCO 2026: Impact of Baseline Demographics on Therapy Management in Patients with mCRPC Treated with Talazoparib + Enzalutamide in the TALAPRO-2 Study: Extended Follow-Up

AUA 2026: Association of Serum Kidney Injury Molecule-1 (KIM-1) with Treatment Response and Survival in Metastatic Renal Cell Carcinoma

AUA 2026: Advanced Prostate Cancer - First-Line mCRPC/APMR: How Do I Select the Best Treatment for My Patient?

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Analysis of real-world re-induction outcomes with nadofaragene firadenovec in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer.

Adoption, consistency, and usability of NICE vs EAU guidelines in low- and intermediate-risk NMIBC: a cross-sectional survey of UK urologists.

Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.

FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis.

Impact of Asymptomatic Bacteriuria on the Outcomes and Tolerability of Bacillus Calmette-Guérin Immunotherapy - Beyond the Abstract

Targeting HER2 in Urothelial Carcinoma: Why Histologic Subtypes and Divergent Histologies Matter - Beyond the Abstract

HER2 and Urothelial Carcinoma: Current Understanding and Future Directions - Beyond the Abstract

Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis.

Automated H-Scoring in Muscle-Invasive Bladder Cancer IHC: An Internal Validation Study.

Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability.

External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification Model.

Xpert® bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

Study of Bladder Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02 (RAISE-02)-A Randomized Controlled Non-Inferiority Trial.

Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.

A comparative analysis of variant histology and urothelial bladder cancer following radical cystectomy.

Penile & Urethral Cancers

Immunohistochemistry for p16 and p53 Provides Substantial Agreement With Molecular Tests in Penile Cancer.

Unveiling the variations in penile cancer care: identifying knowledge gaps and research priorities.

Low GATA3 Predicts Worse Survival in Penile Cancer - Beyond the Abstract

Survival Outcomes of Penile Cancer Patients undergoing Primary Surgery: Experience from a Tertiary Cancer Care Centre in South India.

Complications after sentinel node biopsy and inguinal lymph node dissection in penile cancer: a Danish national cohort study.

Renal Cancer

Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based Combinations.

A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients.

Outcomes of Immune-Checkpoint Inhibitor Rechallenge in Metastatic Clear-Cell Renal Cell Carcinoma: Results from a Global Real-World Evidence Study - Beyond the Abstract

Contemporary Validation of the Renal Cell Carcinoma Inflammatory Score (RISK) for Preoperative Prognostication in Non-Metastatic Renal Cell Carcinoma.

Hereditary kidney tumor syndromes: structured evaluation of a questionnaire-based approach.

Explainable machine learning/artificial intelligence model for estimating postoperative survival in renal cell carcinoma brain metastasis patients.

Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European Americans.

Iceball Margin ted with Local Failure after CT-guided Cryoablation of cT1a Renal Cell Carcinoma

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.

Feasibility and Safety of a Ketogenic Diet During Systemic Therapy for Metastatic Renal Cell Carcinoma: Results from the Cetorein Pilot Study.

Case Report: donor cell-derived leukemia after allogeneic stem cell transplantation for metastatic renal cell carcinoma.

Clinicopathologic features and survival disparities in early onset clear cell renal cell carcinoma in Texas.

Pembrolizumab plus High-Dose IL-2 in Advanced Clear Cell Renal Cell Carcinoma: Six-Year Survival Outcomes and Molecular Signatures from a Phase 2 Trial - Beyond the Abstract

Prostate Cancer

Single-port robotic radical prostatectomy: early results from a UK centre.

Integrative Oncology for Prostate Cancer: A Narrative Review.

3D Genome Architecture and Epigenetic Regulation of Lineage Identity in Advanced Prostate Cancer.

Targeted Prostate Health Checks for prostate cancer in men at high risk: a feasibility pilot in primary and secondary care in North East London.

Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials.

Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance.

New Swedish Biopsy Needle Receives FDA Approval – Secures SEK 17 Million in Capital

da Vinci® single-port versus da Vinci® Xi multiport robot-assisted radical prostatectomy for localized prostate cancer: a GRADE-assessed systematic review and meta-analysis.

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.

Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostate 18F/68Ga-PSMA PET/MRI.

International Delphi consensus on single-port robotic radical prostatectomy: patient selection, surgical technique, and training.

Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer.

Micro-ultrasound guided versus multiparametric MRI-guided prostate biopsy: a systematic review and meta-analysis.

HSD3B1 links ileal steroid metabolism to bile acid regulation in patients with prostate cancer.

Digital pathology for repeat prostate biopsy reassessment during active surveillance: an institutional experience.

Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models.

PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED).

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

Comparative real-world analysis of stereotactic body radiotherapy versus conventional radiotherapy for Chinese patients with low- to intermediate-risk localised prostate cancer.

Risk-Adapted Follow-up after Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study with Diagnostic Stewardship Modeling - Beyond the Abstract

Mevrometostat in Advanced Prostate Cancer: Targeting EZH2 Across the Disease Continuum Through the MEVPRO Clinical Trial Program

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy.

Phenotyping Prostate Cancer in a National Health System Using Large Language Models.

Impact of PSMA-Based Radiopharmaceuticals on the Clinical Management of Prostate Cancer.

Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.

Expression of progranulin (GP88) protein appears as an independent prognostic factor for clinical progression in high-risk prostate cancer patients.

How Will PSMAddition Impact the Management of Prostate Cancer?

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

FDA Approves Truqap Combination for PTEN-Deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results.

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Cell-free DNA in prostate cancer and treatment selection.

Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.

LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Testosterone-Sparing Treatment Strategies for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy - Beyond the Abstract

Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Study - Beyond the Abstract

Upper Tract Tumors

Development and multicohort validation of an interpretable postoperative model for intravesical recurrence after radical nephroureterectomy in upper tract urothelial carcinoma.

Detection of a group of classic serum tumor markers (CSTMs) aids in the differential diagnosis and disease assessment of upper tract urothelial carcinoma (UTUC).

Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomes.

Testicular Cancer

Hyperaccuracy Three-Dimensional Model and Augmented Reality/Mixed Reality for Robot-Assisted Retroperitoneal Lymph Node Dissection in Testicular Cancer.

Pulmonary Fibrosis and Pulmonary Function in Patients with Metastatic Testicular Cancer During and after Combination Chemotherapy: The BLEOTOX Study.

Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC